Otsuka & Click Therapeutics Announce The Launch Of Rejoyn™ Prescription Digital Therapeutic For Major Depressive Disorder

Otsuka Precision Health, Inc. (Otsuka) and Click Therapeutics, Inc., (Click) announced the launch of Rejoyn™, the first-and-only prescription digital therapeutic (PDT) to treat adults with major depressive disorder (MDD) symptoms aged 22 years and older who are on an antidepressant medication. Rejoyn has been cleared by the Food and Drug Administration (FDA) as an adjunct to clinician-managed outpatient care and antidepressant medications. The app is expected to be available for download from app stores for iOS® and Android™ operating systems in the second half of 2024.

The Rejoyn PDT provides six weeks of clinically-validated cognitive emotional . . .